APC-INDEPENDENT EXPANSION OF IMMUNOREGULATORY TR1 CELLS FROM STEM CELL SOURCES FOR ADOPTIVE IMMUNOTHERAPY
Morales-Tirado, V., Van Der Merwe, M., Luszczek, W., Pillai, A. St. Jude Children's Research Hospital, Memphis, TN Immunotherapy with both adaptive and innate regulatory T cells facilitates induction of transplant tolerance, including the prevention and treatment of GVHD. Current strategies to expand regulatory Tr1 cells from CD3 1 CD4 1 CD25 neg conventional T cells include culture with IL-10 and APCs (Groux, et al., Nature, 1997; Gregori et al., Methods Mol. Biol., 2007) and a non-APC dependent protocol utilizing anti-CD3 and IL-2 combined with antibody cross-linking of the innate complement inhibitor I cofactor protein (CD46) (Kemper et al., Nature, 2003) . Optimizing a robust APC-independent means of Tr1 cell generation is of particular utility to hematopoietic cell transplant (HCT) immunotherapy, as it offers potential for large-scale Tr1 cell expansion from autologous or allogeneic cell sources without need for re-separation of Tr1 cells from host or donor APCs prior to infusion. To determine the optimal methods and cellular products for non-APC-dependent expansion of Tr1 suppressors, we performed anti-CD46-mediated expansion of Tr1 cells for 21-28 days from various potential cellular therapy sources. CD3 1 CD4 1 CD25 neg cells were FACS-isolated at . 98% purity and underwent parallel ex vivo expansions from adult peripheral blood apheresis units (PB-Tr1), adult bone marrow (BM-Tr1) and cord blood (CB-Tr1) using low-dose IL-2, anti-CD3, and antibody-crosslinking of CD46, without addition of IL-10 or APCs, to derive a uniform population of CD3 1 CD4 1 CD25 int/1 Foxp3 lo cells (. 95% conversion of CD25 neg Foxp3 lo to CD25 int/1 Foxp3 lo cells, regardless of cellular product type). Differential levels of expansion of Tr1 cells occurred according to the source of cell product, with greatest foldexpansion in PB-Tr1 [mean absolute numbers at day 21 from y10 5 starting CD3 1 CD4 1 CD25 neg cells: PB-Tr1 (n 5 3): 2.5 6 0.8 Â 10 7 ; BM-Tr1 (n 5 2): 7.2 Â 10 5 ; CB-Tr1 (n 5 4): 5.6 6 0.3 Â 10 5 ]. By day 14-21 of expansion, PB-Tr1 cells secrete IL-10 and IL-5, very low levels of IL-2 and IFN-g, and no IL-4 or IL-17 by anti-CD2/CD3/CD28 bead stimulation and LuminexÒ supernatant assay, and they demonstrate suppressor function against sorted autologous CFSE-labeled CD3 1 CD4 1 CD25 neg responders in 72-hour MLR using irradiated allogeneic APC stimulators (Table 1) . We are currently optimizing similar protocols for expansion of BM-Tr1 and CB-Tr1 to allow application in tolerance induction and immunotherapy after HCT from each of these cellular therapy sources. We and others have shown that viral infections in allo-HSCT recipients can be prevented/treated by the adoptive transfer of virus-specific CTL. However, conventional CTL manufacture has taken . 3 months. We recently developed a protocol to rapidly generate CTLs (rCTLs) using DCs nucleofected with viral antigen-encoding DNA plasmids as APCs and expansion in a gas permeable bioreactor (G-Rex) in IL71IL4, which reduces manufacturing time to 16 days. To further streamline production without affecting potency, we are now assessing whether multivirus CTL can be generated by directly stimulating donor PBMCs with clinically applicable pepmixes (15mer peptide libraries) spanning viral antigens.
We isolated PBMCs from 4 healthy donors and generated rCTL using plasmid-nucleofected DCs or by directly stimulating bulk PBMCs using pepmixes spanning the same antigens encoded by the plasmids (EBV-EBNA1, LMP2, BZLF1; CMV-IE1, pp65 and Adv-Hexon, Penton) (pCTL). Subsequently the activated cells were expanded as outlined above. We compared the phenotype, proliferation, specificity and function of each cell population. There was no significant difference in the rate of expansion (rCTL vs pCTL, 8.6 vs 7.1 fold). Similarly, both were phenotypically indistinguishable, with a dominance of CD4 T cells (70.5 vs 74.2%) expressing CD62L (77 vs 61%). Both rCTL and pCTL were specific for the stimulating antigens as measured by IFNg ELIspot with a median of 100 vs 55 EBNA1, 45 vs 47 LMP2, 55 vs 32 BZLF1, 195 vs 232 IE1, 3927 vs 4472 pp65, 525 vs 535 Hexon, 372 vs 782 Penton SFC/1x10 6 CTL. rCTL and pCTL lysed EBV (16 vs 19%), Adv (27 vs 34%) and CMV targets (42 vs 49% E:T 80:1). Finally, to evaluate whether stimulation using 15mer peptides, which contain all CD8 but possibly not all CD4 epitopes, results in loss of CD41 specificity we generated pCTL using either 15-or 30mer peptides spanning a region of Hexon predominantly recognized by CD41 T cells. Phenotypically the CTL were similar (CD41 56 vs 60%; CD81 21 vs 16%) and epitope specificity, as evaluated by stimulation with peptide pools, demonstrated slightly broader specificity using 15-over 30mer peptides with a mean of 10 vs 7 pools recognized.
In summary, we can efficiently generate polyclonal multivirus CTLs by directly stimulating PBMCs with pepmixes. This approach is clinically applicable, requires a starting blood volume of only 15ml, and reduces manufacturing time to \ 10 days, with a consequent reduction in cost and complexity. Bone marrow stromal cell (BMSC) therapy is effective for treating acute-Graft versus Host Disease. Clinical BMSCs are produced by serial passage of adherent cells from marrow aspirates. Multiple passages allow for the production of large quantities of human BMSCs, but expansion is limited by cell senescence. We assessed the nature of BMSC changes associated with multiple passages in order to better understand the nature and impact of senescence on human BMSCs and to identify potential senescence associated biomarkers. BMSCs from marrow aspirates of 5 healthy subjects were cultured in flasks and passed serially until cell growth stopped between the 8 th to 12 th passages. Early (passage 1 and 2, n10) and late passage cells (passages 5 through 11, n15) were selected based on their replicative lifespan and compared. Senescence was associated with a change to a flattened morphology and increased senescence associated beta-galactosidase (SA b-gal) staining. The BMSCs were analyzed by global transcriptome analysis with an oligonucleotide microarray with .44,000 probes. Unsupervised hierarchical clustering analysis separated the 25 samples into two clusters, one with all early and a second with all late passage BMSCs and a total of 1,739 genes were differentially expressed. Ingenuity pathway analysis revealed that genes highly expressed in the early passage BMSCs belonged to several immune pathways: cell-mediated immune response, humoral immune responses, hypersensitive responses, and lymphoid tissue structure and development. Genes highly expressed in the late passage BMSCs belonged S216 Poster Session I
